World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
51
Citations
11781
World Ranking
4129
National Ranking
1884

Best Publications

  • Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population.

    David R. Bangsberg;Frederick M. Hecht;Edwin D. Charlebois;Andrew R. Zolopa

  • Non-adherence to highly active antiretroviral therapy predicts progression to Aids

    David R. Bangsberg;Sharon Perry;Edwin D. Charlebois;Richard A. Clark

  • Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: a multicenter randomized strategy trial

    Andrew R. Zolopa;Janet Andersen;Lauren Komarow;Ian Sanne

  • Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks

    Paul E. Sax;Edwin DeJesus;Anthony Mills;Andrew Zolopa

  • The relation between baseline HIV drug resistance and response to antiretroviral therapy: re-analysis of retrospective and prospective studies using a standardized data analysis plan

    Victor DeGruttola;Lynn Dix;Richard D'Aquila;Dan Holder

  • High levels of adherence do not prevent accumulation of HIV drug resistance mutations.

    David R Bangsberg;Edwin D Charlebois;Robert M Grant;Mark Holodniy

  • Inflammation and mortality in HIV-infected adults: analysis of the FRAM study cohort.

    Phyllis C Tien;Andy I Choi;Andrew R Zolopa;Constance Benson

  • Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-Infected, treatment-experienced patients: AIDS clinical trials group 5211.

    Roy M. Gulick;Zhaohui Su;Charles Flexner;Michael D. Hughes

  • Mutation patterns and structural correlates in human immunodeficiency virus type 1 protease following different protease inhibitor treatments.

    Thomas D. Wu;Celia A. Schiffer;Matthew J. Gonzales;Jonathan Taylor

  • HIV and tuberculosis infection in San Francisco's homeless adults. Prevalence and risk factors in a representative sample.

    Andrew R. Zolopa;Judith A. Hahn;Robert Gorter;Jeanne Miranda

  • HIV-1 genotypic resistance patterns predict response to saquinavir-ritonavir therapy in patients in whom previous protease inhibitor therapy had failed.

    Andrew R. Zolopa;Robert W. Shafer;Ann Warford;Jose G. Montoya

  • Tenofovir alafenamide vs. tenofovir disoproxil fumarate in single tablet regimens for initial HIV-1 therapy: A randomized phase 2 study

    Paul E. Sax;Andrew Zolopa;Indira Brar;Richard Elion

  • HIV-1 Protease Mutations and Protease Inhibitor Cross-Resistance

    Soo-Yon Rhee;Jonathan Taylor;W. Jeffrey Fessel;David Kaufman

  • A randomized double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: analysis of week 96 results.

    Andrew Zolopa;Paul E. Sax;Edwin Dejesus;Anthony Mills

  • Risk Factor Analyses for Immune Reconstitution Inflammatory Syndrome in a Randomized Study of Early vs. Deferred ART during an Opportunistic Infection

    Philip M. Grant;Lauren Komarow;Janet Andersen;Irini Sereti

  • Antiviral Activity of Lamivudine in Salvage Therapy for Multidrug-Resistant HIV-1 Infection

    Thomas B. Campbell;Nancy S. Shulman;Steven C. Johnson;Andrew R. Zolopa

  • Evidence for Genetic Regulation of Susceptibility to Toxoplasmic Encephalitis in AIDS Patients

    Yasuhiro Suzuki;Sin-Yew Wong;F. Carl Grumet;Jeffrey Fessel

  • Phase I/II study of the pharmacokinetics, safety and antiretroviral activity of tenofovir alafenamide, a new prodrug of the HIV reverse transcriptase inhibitor tenofovir, in HIV-infected adults

    Martin Markowitz;Andrew Zolopa;Kathleen Squires;Peter Ruane

  • HIV-1 Protease and Reverse-Transcriptase Mutations: Correlations with Antiretroviral Therapy in Subtype B Isolates and Implications for Drug-Resistance Surveillance

    Soo-Yon Rhee;W. Jeffrey Fessel;Andrew R. Zolopa;Leo Hurley

  • Extended spectrum of HIV-1 reverse transcriptase mutations in patients receiving multiple nucleoside analog inhibitors

    Matthew J. Gonzales;Thomas D. Wu;Jonathan Taylor;Ilana Belitskaya

Frequent Co-Authors

Jeanne Miranda
Jeanne Miranda University of California, Los Angeles
Louise Pilote
Louise Pilote McGill University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Best Scientists Citing Andrew R. Zolopa

Recently Published Articles